Study seeks to recruit up to 45 adults with severe sickle cell disease
WEDNESDAY, July 31, 2019 (HealthDay News) — A U.S. clinical trial of CRISPR gene-editing to treat people with sickle cell disease is underway.
The trial seeks to recruit up to 45 adults with severe sickle cell disease. It will use CRISPR in an attempt to boost production of a different kind of hemoglobin (fetal hemoglobin) that makes it harder for cells to sickle and stick together, CNN reported.
Sickle cell disease affects about 100,000 Americans, most of African ancestry or identifying as black.
“This is an extraordinary time” in the treatment of sickle cell disease, Alexis Thompson, M.D., hematology section head at the Ann and Robert H. Lurie Children’s Hospital of Chicago, who is not involved in the trial, told CNN. “It’s terribly exciting that there is so much attention on cutting-edge science and a condition that has lagged far behind many other medically important diseases.”
Gene Mutation Identified That Increases Lung Cancer Risk 
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50 
Family History of CRC Increases CRC Risk Similarly in IBD, General Population 
Relapse Rare After Appendiceal Adenocarcinoma Resection .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Implant, Patient Survival Do Not Differ for Robotic and Conventional Total Joint Replacement 
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers 
Physical Therapist-Supervised Exercise Improves Outcomes After ACL Reconstruction 
